PRP4K and ovarian carcinoma: Moreover, they found that among a taxane-treated cohort of ovarian cancer patients, the patients harboring tumours with high PRP4K protein levels, and low levels of HER2 expression, exhibited better overall survival (Corkery et al., 2015b); evidence supporting a potential role for PRP4K as a predictive biomarker for taxane response in ovarian cancer.